Clinical trial
Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate in…
NCT02234115 · Foresee Pharmaceuticals Co., Ltd., Industry · Completed
Key facts
| NCT number | NCT02234115 |
|---|---|
| Title | Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate in Subjects With Advanced Prostate Carcinoma |
| Official title | An Open-Labeled, Singled-Arm Study of the Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate for Injectable Suspension (LMIS 50 mg) in Subjects With Advanced Prostate Carcinoma |
| Lead sponsor | Foresee Pharmaceuticals Co., Ltd., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Prostatic Neoplasms |
| Intervention type | Drug |
| Interventions | Leuprolide Mesylate |
| Enrollment | 137 |
| Start date | Aug 1, 2014 |
| Primary completion | Aug 30, 2016 |
| Completion | Jan 5, 2017 |
| First posted | Sep 9, 2014 |
| Last update posted | Mar 5, 2019 |
| Countries | Austria, Czechia, Germany, Lithuania, Poland, Slovakia, Taiwan, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: